… at increased risk of bleeding. We investigated the use of a prothrombin complex concentrate
(… The time of dosing depended on clinical circumstances, as soon as major bleed suspected …

… prothrombin complex concentrate (4F-PCC) as an alternative for managing direct FXa
inhibitor–related major bleeding… for direct FXa inhibitor–related major bleeding were included. The …

… bleeding has been described in small case series and one cohort study. Patients on apixaban
or rivaroxaban, suffering a major bleed, … We recruited 66 patients with major bleeding who …

… acute major bleeding or need for an urgent surgery/invasive procedure (Table 2; Fig. 2).
KCentra® (CSL Behring, King of Prussia, PA) is the only 4-factor formulation approved for this …

… Prothrombin complex concentrate (PCC) is increasingly being used as a treatment for major
bleeding in … administration for the treatment of bleeding in patients not taking anticoagulants. …

… because only surrogate markers of bleeding were used, by the small sample size, and the
fact that the study did not include patients experiencing major bleeding or requiring invasive …

… with prothrombin complex concentrates (PCCs) for the management of major bleeding events
(… the assessment of the effectiveness of major bleeding management. The safety outcomes …

… Patients experiencing major bleeding while taking vitamin K antagonists require rapid vitamin
K … trial to compare nonactivated 4-factor prothrombin complex concentrate (4F-PCC) with …

… or prophylaxis of bleeding in congenital … is bleeding. In large-scale epidemiological
studies on patients receiving oral anticoagulant therapy, the annual incidence of major bleeding …

… To review the evidence supporting the use of prothrombin complex concentrate (PCC) as a
… The search terms used were prothrombin complex concentrate, hemorrhage, and bleeding. …